Dr Keegan has more than 30 years of experience in life science businesses. He was CEO at ForteBio Inc, a life science tool company when it was sold to Pall Corporation. While at the helm he established product development and sales strategies for the company. Prior to that, Dr Keegan was CEO at Molecular Devices Inc (NASDAQ: MDCC), a provider of bioanalytical measurement systems, software and consumables. He is a member of the board of directors of Bio-Techne (NASDAQ: TECH) and Interpace Biosciences Inc (NASDAQ: IDXG). Dr Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.

Hywel joined Nuclera as a scientific advisor in 2018. He is Professor of Bioelectronics at the University of Southampton and specializes in bio-sensors, nanotechnology and lab-on-a-chip technologies. Prof. Morgan completed a PhD in biophysics. He has been awarded a Royal Society-Leverhulme Senior Research Fellowship at the University of Oxford and the Desty memorial prize for innovation in separation science. Prof. Morgan is a Fellow of the Institute of Physics, the Royal Society of Chemistry, and the IET. He holds a Royal Society Wolfson research merit award. He is also co-founder and Director of VivoPlex, a company developing implantable vital signs sensors.